论文部分内容阅读
Objective:To investigate the difference of peripheral blood sIL-2R before and after chemotherapy in breast cancer patients,and evaluate the clinical value of the sIL-2R in breast cancer’s diagnosis and therapy.Methods:The peripheral blood sIL-2R levels of the breast cancer patients with or without chemotherapy were detected by ELISA.The healthy persons were made as the control group.Results:The slL-2R levels of the breast cancer patients were higher than that of the control group(P＜0.05);the slL-2R’s levels in Ⅰ～Ⅱ stage breast cancer were lower than that in Ⅲ～Ⅳ stag e breast cancer (P＜0.05);the sIL-2R levels of the patients before chemotherapy were higher than that of the patients undergone chemotherapy(P＜0.05);The level of the patient with chemotherapy was still higher than that of the control group(P＜0.05);the sIL-2R levels of the patients whose chemotherapies were noneffective were higher than that of the patients received effective chemotherapies(P＜0.05).There was no significant difference between the group with ER(+)or PR(+)and the group with ER(-)or PR(-)(P＞0.05).Conclusion:The breast cancer patients have the high slL-2R levels.There is a close relationship between the cancer incidence and the patients,immune situation.The level of slL-2R could be a clinical index which Can be used for evaluating the cancer degree,because the higher levels of slL-2R can indicate that the immune ability of patient is worse.There is a significant difference between the slL-2R levels of the patients before chemotherapy and that of the patients undergone chemotherapy.